BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our passionate interest in fighting cancer.
General Description:
We are looking for a detail-oriented and collaborative OTC Specialist to join our Finance team. In this role, you will support the several subprocesses in the order-to-cash, collaborating with the commercial operations of a fast-growing biotech company. You will work cross-functionally with Commercial Operations, GL Accounting, and external customers to maintain healthy receivables and minimize credit risk while delivering a high-quality customer experience. The ideal candidate brings solid experience in Accounts Receivable and OTC accounting, hands-on SAP S/4HANA experience, strong analytical skills, and the ability to thrive in a dynamic, fast-paced environment.
This role has hybrid work pattern, 3 days per week from our Warsaw office with 2 days remote.
AR & Cash Application
Collections & Dunning
ERP & Systems
Education Required: Accounting / Business / Finance Bachelor's Degree
Requirements:
Travel: Minimum
Global Competencies
When we exhibit our values of Patients First, Driving Excellence, Bold Ingenuity, and Collaborative Spirit, through our twelve global competencies below, we help get more affordable medicines to more patients around the world.
We are proud to be an equal opportunity employer. BeOne does not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, disability, national origin, veteran status or any other basis covered by appropriate law. All employment is decided on the basis of qualifications, merit, and business need.

Effective March 17, 2025, The U.S. subsidiary of BeiGene, Ltd. has changed its name to BeOne Medicines USA, Inc. This change comes ahead of our anticipated global rebranding to BeOne Medicines Ltd. and redomiciliation to Switzerland, pending shareholder approval. The new name reflects our commitment to develop innovative medicines and partner with the global community to help as many patients with cancer as possible.
To learn more about BeOne Medicines, please follow our new LinkedIn profile @BeOne Medicines.